Comparative Pharmacology
Head-to-head clinical analysis: ACTOPLUS MET versus ROSIGLITAZONE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTOPLUS MET versus ROSIGLITAZONE MALEATE.
ACTOPLUS MET vs ROSIGLITAZONE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Actoplus Met combines pioglitazone, a thiazolidinedione that improves insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPARγ), and metformin, a biguanide that decreases hepatic glucose production and improves peripheral glucose uptake.
Rosiglitazone is a thiazolidinedione that acts as a selective agonist at peroxisome proliferator-activated receptor-gamma (PPARγ). Activation of PPARγ increases insulin sensitivity in adipose tissue, skeletal muscle, and liver, leading to reduced hepatic gluconeogenesis and increased glucose uptake.
ACTOPLUS MET (pioglitazone/metformin) is available as tablets of 15 mg/500 mg, 15 mg/850 mg, and 15 mg/1000 mg. The usual starting dose is 15 mg/500 mg twice daily or 15 mg/850 mg once daily, gradually titrated based on glycemic response and tolerability. Maximum recommended dose is 45 mg pioglitazone and 2000 mg metformin per day.
4 mg orally once daily; may increase to 8 mg once daily after 12 weeks if inadequate glycemic response.
None Documented
None Documented
Pioglitazone: terminal half-life 3–7 hours (parent drug) for elimination, with active metabolites prolonging clinical effects up to 24 hours. Metformin: 6.2 hours (plasma), prolonged to 17.6 hours in renal impairment (e.g., CrCl <60 mL/min).
Terminal elimination half-life is 3-4 hours; clinically relevant as dosing is twice daily to maintain steady-state concentrations.
Pioglitazone: predominantly hepatic metabolism and biliary excretion of metabolites, with 15–30% recovered in urine (mostly metabolites) and the remainder in feces. Metformin: 90% excreted unchanged in urine via glomerular filtration and tubular secretion, with <10% in feces.
Primarily hepatic metabolism via CYP2C8, with less than 1% excreted unchanged in urine. Fecal excretion of metabolites accounts for approximately 64% and renal excretion for 23% of the dose.
Category C
Category A/B
Thiazolidinedione/Biguanide Combination
Thiazolidinedione